Get started
Author

Michael Aristides

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
2004 · T. Le Chevalier, G. Scagliotti, et al. · Lung Cancer · 276
Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery
1994 · M Drummond, M Aristides, et al. · British journal of surgery · 73
Patient Preference and Willingness-to-Pay for Humalog Mix25 Relative to Humulin 30/70: A Multicountry Application of a Discrete Choice Experiment
2004 · Michael Aristides, Adèle R. Weston, et al. · Value in Health · 65
Economic Impact of Increased Clinical Intervention Rates in Community Pharmacy
2000 · Shalom I. Benrimoj, Jane H. Langford, et al. · PharmacoEconomics · 57
Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe
2003 · Joan Schiller, Dominic Tilden, et al. · Lung Cancer · 45
Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
2002 · M. Lees, M. Aristides, et al. · PharmacoEconomics · 44
Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis
1997 · Peter Davey, David Grainger, et al. · Clinical Therapeutics · 34
Cost–effectiveness of vitamin E therapy in the treatment of patients with angiographically proven coronary narrowing (CHAOS trial)
1998 · Peter J Davey, Mark Schulz, et al. · The American Journal of Cardiology · 24
Cost-Effectiveness of Pergolide Compared to Bromocriptine in the Treatment of Parkinson's Disease: A Decision-Analytic Model
2001 · Peter Davey, Narayan Rajan, et al. · Value in Health · 22
Cost–utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer
2004 · Paul Robinson, Hans von der Maase, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 20
The effects on hospital use and costs of a domiciliary palliative care nursing service.
1993 · M Aristides, A Shiell · PubMed · 7
769 Reducing health care burden for the treatment of toxicity associated with pemetrexed or docetaxel in patients with advanced non-small cell lung cancer who previously received chemotherapy: application to the UK setting
2003 · L. Bushill-Matthews, D. Jackson, et al. · European Journal of Cancer Supplements · 6
Pcn4 Retrospective Cost Analysis of Gemzartm in Combination With Cisplatin in Non-small Cell Lung Cancer Compared to Other Combination Therapies in Germany
2002 · A Kielhorn, N Maniadakis, et al. · Value in Health · 6
PDF
Pcn19 Examining Preferences and Timetrade-off Utility for Gemcitabine Plus Cisplatin in the Treatment of Bladder Cancer:a Survey Using Discrete Choice Conjoint Analysis in the Uk
2002 · A Brown, M Aristides, et al. · Value in Health · 5
PDF
Cost-effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer
2005 · N. Pavlakis, P. L. Mitchell, et al. · Journal of Clinical Oncology · 4
Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer
2005 · M. ARISTIDES, H. VON DER MAASE, et al. · European Journal of Cancer Care · 4
PDF
Pdb10 the Cost-effectiveness of Pioglitazone in Combination With Metformin in the Treatment of Type 2 Diabetes Mellitus in Scotland
2004 · G Stynes, D Tilden, et al. · Value in Health · 3
Pcn46 a Cost Utility Analysis of Maintenance Rituximab for the Treatment of Relapsed/refractory Follicular Non Hodgkins Lymphoma (nhl) in the United Kingdom
2007 · U Geary, G Lewis, et al. · Value in Health · 2
Par10 Cost-effectiveness of Rituximab Therapy for Rheumatoid Arthritis: a Pan-european Analysis
2006 · A Kielhorn, A Rubbert, et al. · Value in Health · 2
PDF
Pcn7: Economic Evaluation of Gemzar and Best Supportive Care (bsc) Relative to Best Supportive Care Alone in the Treatment of Non Small Cell Lung (nsclc) Cancer in the Uk
2001 · J McKendrick, N Botwood, et al. · Value in Health · 2
Patients value the clinical characteristics and convenience of Humalog® mix25™: Results of a willingness to pay study in patients with type 2 diabetes
2000 · Peter Davey, Narayan Rajan, et al. · Diabetes Research and Clinical Practice · 2
A Principal Component Analysis of Overall Survival Outcomes and List Prices of Oncology Drugs in Europe
2016 · M Zhu, C Quinn, et al. · Value in Health · 1
Pdb23 Cost-effectiveness of Biphasic Insulin Aspart 30 Versus Human Premix Insulin for Type 2 Diabetes Patients in a Polish Setting
2007 · M Aristides, R Kotchie, et al. · Value in Health · 1
PDF
Par8 Using Mabthera in Patients With Rheumatic Arthritis in Spain: Results of Cost-effectiveness Data Based on Micro-simulation
2006 · A Kielhorn, C Alvarez, et al. · Value in Health · 1
PDF
Pcn30 Improved Toxicity Profile of Pemetrexedvs Docetaxel in Previously Treated Non-small Cell Lung Cancer Patients Translates to Cost Savings in Spain
2004 · G Stynes, M Aristides, et al. · Value in Health · 1
Works count: 55
Citation count: 710
H-index: 10
I10-index: 10
Year
Topic
Type